31.75
-0.41(-1.27%)
Currency In USD
| Previous Close | 32.16 |
| Open | 31.75 |
| Day High | 32.02 |
| Day Low | 31.38 |
| 52-Week High | 46.48 |
| 52-Week Low | 21.16 |
| Volume | 1.85M |
| Average Volume | 2.14M |
| Market Cap | 5.04B |
| PE | 85.81 |
| EPS | 0.37 |
| Moving Average 50 Days | 32.43 |
| Moving Average 200 Days | 34.39 |
| Change | -0.41 |
If you invested $1000 in TG Therapeutics, Inc. (TGTX) 10 years ago, it would be worth $2,709.04 as of September 16, 2025 at a share price of $31.75. Whereas If you bought $1000 worth of TG Therapeutics, Inc. (TGTX) shares 5 years ago, it would be worth $1,278.18 as of September 16, 2025 at a share price of $31.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
GlobeNewswire Inc.
Sep 10, 2025 11:30 AM GMT
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
GlobeNewswire Inc.
Sep 08, 2025 11:30 AM GMT
Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimensNEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (u
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 04, 2025 11:30 AM GMT
Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ETNEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will pa